))
Let's Talk MND - Michael Thurn CEO PharmAust
Manage episode 430684528 series 3562494
Content provided by Jane Simpson. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Jane Simpson or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Our guest this week is Michael Thurn the CEO and Managing Director of PharmAust, a clinical-stage biotechnology company.
He tells us about Monepantel which is a well-known veterinary drug. It has been shown to have an effect on the abnormal accumulation of protein in cells. This accumulation is associated with motor neurone disease. Monepantel works by increasing the recycling and removal of excessive or abnormal proteins.
Results from phase 1 of this trial suggest that monepantel was well tolerated. In fact it showed a slowing in progression of MND.
In July of 2024 Monepantel has been included in the Healy ALS trials, in Boston, USA, which means the study will be fast tracked.
To learn more about the studies please go to
33 episodes
Share
